Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Nereid Therapeutics General Information
Nereid is developing technologies to visualize and measure liquid-liquid phase separation in cells and discover small molecules that can modulate protein interactions in disease states. The company has demonstrated translatability of chemical matter that modulates LLPS behavior to disease-relevant cellular phenotypes and is progressing several programs in cancer and other diseases.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Nereid Therapeutics Funding
No funding data available
To view Nereid Therapeutics's complete valuation and funding history, request access »